Biocryst Pharmaceuticals (BCRX) Cash & Equivalents (2010 - 2026)

Biocryst Pharmaceuticals (BCRX) has 17 years of Cash & Equivalents data on file, last reported at $854000.0 in Q1 2026.

• Quarterly Cash & Equivalents rose 193.47% year-over-year to $854000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $854000.0 (up 193.47% YoY) and the FY2025 annual result came in at $201000.0, down 99.81% from the prior year.
• Cash & Equivalents rose to $854000.0 in Q1 2026, from $201000.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $395.5 million in Q1 2022 to a low of $201000.0 in Q4 2025.
• A 5-year average of $91.2 million and a median of $84.1 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents surged 9767.86% — and 2025, when it slumped 99.81%.
• Tracing BCRX's Cash & Equivalents over 5 years: stood at $1.5 million in 2022, then soared by 7416.51% to $110.6 million in 2023, then slipped by 5.36% to $104.7 million in 2024, then tumbled by 99.81% to $201000.0 in 2025, then soared by 324.88% to $854000.0 in 2026.
• The last three Cash & Equivalents figures came in at $854000.0 (Q1 2026), $201000.0 (Q4 2025), and $84.1 million (Q3 2025), per Business Quant data.